Novo Nordisk A/S (Novo Nordisk A/S) Total Liabilities : $30,422 Mil (As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk A/S Total Liabilities?

Novo Nordisk A/S's Total Liabilities for the quarter that ended in Dec. 2023 was $30,422 Mil.

Novo Nordisk A/S's quarterly Total Liabilities increased from Jun. 2023 ($27,689.58 Mil) to Sep. 2023 ($29,639.22 Mil) and increased from Sep. 2023 ($29,639.22 Mil) to Dec. 2023 ($30,421.52 Mil).

Novo Nordisk A/S's annual Total Liabilities increased from Dec. 2021 ($18,805.96 Mil) to Dec. 2022 ($22,465.22 Mil) and increased from Dec. 2022 ($22,465.22 Mil) to Dec. 2023 ($30,421.52 Mil).

Novo Nordisk A/S Total Liabilities Historical Data

The historical data trend for Novo Nordisk A/S's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Total Liabilities Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

10,117.51

13,342.87

18,805.96

22,465.22

30,421.52

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															22,465.22	24,474.41	27,689.58	29,639.22	30,421.52

Novo Nordisk A/S Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Novo Nordisk A/S's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	24822.233	+	(3003.453	+	1000.468
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1486.803	+	108.562)
	=	30,422

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	46012.466	-	15590.946
	=	30,422

Novo Nordisk A/S's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	24822.233	+	(3003.453	+	1000.468
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1486.803	+	108.562)
	=	30,422

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	46012.466	-	15590.946
	=	30,422

Novo Nordisk A/S Total Liabilities Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.